AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04524312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
Study NCT04524312 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biomechanics
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
Study NCT04524312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Ps or Bioimplanti K-MOD implant
Description: Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
Study NCT00902642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level
Description: an eight day university training course on psychosocial factors for physical therapists
Study NCT00649064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
Study NCT00974571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
Study NCT00974571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: cetirizine
Description: cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
Study NCT00974571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet orally once daily at bedtime for 6 weeks
Study NCT01573780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smac mimetic TL32711
Description: Given IV
Study NCT01573780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01573780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01573780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01573780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT03897790 — intervention group
Intervention type: OTHER
Intervention: Transcranial Doppler (DTC)
Description: Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
Study NCT04392856 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Same than experimental condition (UP), after it finishes
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
Study NCT03929965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib
Study NCT04065789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
Study NCT04065789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
Study NCT04065789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
Study NCT04065789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
Study NCT03718611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9001
Description: BR9001 is a test drug as generic
Study NCT03718611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR900A
Description: BR900A is a reference drug
Study NCT02332525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Vibrational Stimulation
Description: Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place.
Study NCT04415580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation (VR)
Description: VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right).
Study NCT00804336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
Study NCT00804336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Given orally once a day
Study NCT03831711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT03831711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational software and coils in PET/MR scan
Description: General Electric (GE) Healthcare non-approved PET scanner coils and software
Study NCT02620098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Size Matters Handwriting Program
Description: The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
Study NCT01105507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab (company code: ACZ885D)
Study NCT04415580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Neurorehabilitation
Description: muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
Study NCT01906073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl spray
Study NCT01906073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: slow release morphine
Study NCT02334202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Weight Gain
Description: Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
Study NCT02334202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
Study NCT02232009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3.0 T Neonatal MRI Scanner
Description: Eligible subjects will undergo neonatal MRI scanning procedures.
Study NCT02181192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT
Study NCT02181192 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Instant Radiotherapy according to guidelines
Description: Instant Radiotherapy according to guidelines
Study NCT02181192 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy after achievement of PSA marginal value
Description: Radiotherapy after achievement of PSA marginal value
Study NCT03358485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aolanti Weikang tablets
Description: Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
Study NCT03358485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05291364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
Study NCT05291364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
Study NCT00543049 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
Study NCT00543049 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SUNITINIB
Description: Sunitinib, oral, 37,5 mg once daily continuously, up to one year
Study NCT02568202 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment.
Study NCT03536520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study NCT03536520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study NCT00984334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 5 mg capsules
Study NCT00984334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00984334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 10 mg capsules
Study NCT00984334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone SR 20mg capsules
Study NCT00984334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone SR 2.5 mg capsules
Study NCT02920645 — intervention group
Intervention type: OTHER
Intervention: AVM-related ICH
Study NCT00554905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
Study NCT00554905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
Study NCT00554905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first, then RFA within 2 weeks
Study NCT02781233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Progressive resistance training program
Study NCT02781233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal daily activities
Description: Usual daily activities
Study NCT02259959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single rising doses of BI 1744 CL, solution for oral inhalation
Study NCT04604353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score
Description: Risk description to patient based on PRS
Study NCT04604353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Calcium Score
Description: Risk description to patient based on CCS
Study NCT01945034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IBU twice daily
Description: Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
Study NCT01945034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo twice daily
Description: Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
Study NCT01945034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IBU three times daily
Description: Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
Study NCT01945034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times daily
Description: Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
Study NCT04941014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
Study NCT04941014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
Study NCT04941014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vigourous Physical Activity
Description: The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
Study NCT00937859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: SER120
Study NCT00937859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02259959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium, fixed dose, solution for oral inhalation
Study NCT02259959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05890235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ningmitai Capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Study NCT05890235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai Capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
Study NCT05890235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Study NCT01489306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 10 day period
Study NCT01489306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 10 day period
Study NCT02325739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF401
Description: FGF401 is a FGFR4 inhibitor.
Study NCT01167816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticposteroids (ICS)
Description: Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticposteroids (ICS)
Description: Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
Study NCT02325739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
Study NCT03296592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI with DBSI technology
Description: The MRI will be done with diffusion basis spectrum imaging
Study NCT03068429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride
Description: first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
Study NCT02665858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OCT Imaging
Study NCT01713374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mental stress
Description: Subjects will be asked to perform complex mathematic operations at a very fast pace
Study NCT01713374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: control visit
Study NCT01713374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myogenic activation
Description: A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.